Mikkel W. Pedersen

Ballerup, 2750, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

A novel SARS-CoV-2 Beta RBD DNA vaccine directly targeted to antigen-presenting cells induces strong humoral and T cell responses.

A novel SARS-CoV-2 Beta RBD DNA vaccine directly targeted to antigen-presenting cells induces strong humoral and T cell responses.

Journal: Scientific reports

Published: January 02, 2023

First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.

First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.

Journal: Investigational new drugs

Published: September 17, 2021

Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype.

Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype.

Journal: Science translational medicine

Published: April 26, 2019

Deep neural networks identify signaling mechanisms of ErbB-family drug resistance from a continuous cell morphology space.

Deep neural networks identify signaling mechanisms of ErbB-family drug resistance from a continuous cell morphology space.

Journal: Cell reports

Published: May 04, 2018

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.

Journal: JAMA oncology

Published: February 10, 2018

Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.

Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 20, 2017

Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.

Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.

Journal: Molecular cancer therapeutics

Published: July 15, 2015

Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance.

Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance.

Journal: Molecular cancer therapeutics

Published: August 19, 2014

Targeting the ERBB family in cancer: couples therapy.

Targeting the ERBB family in cancer: couples therapy.

Journal: Nature reviews. Cancer

Published: August 17, 2013

Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.

Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.

Journal: mAbs

Published: November 30, 2011

Showing 1-10 of 10

Last Updated: 09/26/2026